Issued to PF PRISM CV. Application is approved as submitted.
Posted by FDA
September 21, 2026Application
NDA 505b1 • 203214
Product
XELJANZ / XELJANZ XR
Company
PF PRISM CV
Stage
Final Decision
Assyro regulatory brief
FreeSource facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
FDA posted an approval letter for XELJANZ, XELJANZ XR on 2026-09-21. This is the document posting date; consult the signed letter for the decision date. The source metadata identifies NDA 203214, NDA 208246, NDA 213082 as a supplement. Review the exact FDA letter for the approved conditions and labeling.
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
This letter documents an FDA approval action: FDA approved NDA 203214 for XELJANZ / XELJANZ XR, sponsored by PF PRISM CV,. Product may be marketed. Verify current status and labeling in the source letter, since later FDA actions can change them.
NDA 203214 is the application under which FDA issued this approval letter for XELJANZ / XELJANZ XR to PF PRISM CV. FDA posted the letter on September 21, 2026; the posting date is not the decision date.
The sponsor may market the product in line with the approved labeling. Approval letters typically set post-approval obligations: submitting final content of labeling, meeting any postmarketing requirements or commitments listed in the letter, updating Orange Book patent information within 30 days for NDAs, and ongoing annual reporting under 21 CFR 314.81.